Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Sold by GAM Holding AG

GAM Holding AG reduced its holdings in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) by 16.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,000 shares of the biotechnology company’s stock after selling 1,000 shares during the period. GAM Holding AG’s holdings in Cerevel Therapeutics were worth $204,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Headlands Technologies LLC purchased a new stake in Cerevel Therapeutics in the 1st quarter valued at $26,000. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Cerevel Therapeutics in the fourth quarter valued at about $71,000. Centaurus Financial Inc. acquired a new stake in Cerevel Therapeutics during the fourth quarter worth about $119,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in Cerevel Therapeutics during the second quarter worth about $127,000. Finally, Virtu Financial LLC acquired a new position in Cerevel Therapeutics in the 4th quarter valued at about $246,000. 87.73% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cerevel Therapeutics

In other Cerevel Therapeutics news, Director N Anthony Coles sold 25,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $41.18, for a total transaction of $1,029,500.00. Following the completion of the sale, the director now owns 25,928 shares of the company’s stock, valued at $1,067,715.04. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.10% of the stock is currently owned by insiders.

Cerevel Therapeutics Stock Performance

Shares of Cerevel Therapeutics stock remained flat at $44.96 during mid-day trading on Tuesday. The stock has a 50-day moving average price of $43.02 and a 200-day moving average price of $42.24. The firm has a market capitalization of $8.19 billion, a price-to-earnings ratio of -16.47 and a beta of 1.40. The company has a debt-to-equity ratio of 0.60, a quick ratio of 10.22 and a current ratio of 10.22. Cerevel Therapeutics Holdings, Inc. has a 12 month low of $19.59 and a 12 month high of $44.99.

Cerevel Therapeutics Profile

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.